Proposes offering of 4.7 mil. shares of common stock at between $1.50 and $8 per share, as well as 140,250 shares of Series 1 convertible redeemable preferred stock, 1 mil. Class B warrants and 67,500 common stock purchase warrants. Roughly a third of the common shares are issuable upon exercise of Class A warrants issued in conjunction with the firm's October 1992 acquisition of Quantronix and the restructuring of Quantronix' bank debt ("The Gray Sheet" Aug. 3, 1992, p. 23). Another third underlies Class B warrants currently outstanding and those issuable (with one share of common stock) upon conversion of preferred stock. The developer of laser products for medical and dental applications will use expected net proceeds of approximately $25.3 mil. for research and development, marketing and advertising, working capital, and general corporate purposes.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights